Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results

Accolade (NASDAQ:ACCD) issued its quarterly earnings results on Friday. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01, Zacks reports. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%.

Accolade Stock Performance

NASDAQ:ACCD opened at $6.83 on Friday. Accolade has a fifty-two week low of $3.08 and a fifty-two week high of $15.21. The firm has a market capitalization of $550.07 million, a PE ratio of -6.63 and a beta of 2.08. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72. The stock’s fifty day moving average is $3.73 and its 200 day moving average is $3.82.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Canaccord Genuity Group reiterated a “hold” rating on shares of Accolade in a research report on Wednesday. Leerink Partners reiterated a “market perform” rating on shares of Accolade in a report on Wednesday. Morgan Stanley dropped their target price on Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Wells Fargo & Company decreased their price target on Accolade from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Friday, October 11th. Finally, Raymond James reissued a “market perform” rating on shares of Accolade in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.55.

Insider Buying and Selling at Accolade

In other Accolade news, CEO Rajeev Singh sold 13,357 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total transaction of $48,085.20. Following the completion of the sale, the chief executive officer now owns 814,316 shares in the company, valued at $2,931,537.60. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 40,881 shares of company stock worth $144,987 over the last 90 days. Company insiders own 8.20% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.